A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 75-82

  Lin, Jiang Tao ^a   Yu, Xue Zhong ^b   Cui, De Jian ^c   Chen, Xu Yan ^d   Zhu, Ji Hong ^e   Wang, Yu Zhen ^f   Wu, Xiao Di ^g  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b Peking United Medical Center Hospital   (China)

^c 304TH HOSPITAL   (China)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^f Tianjin Infection Disease Hospital   (China)

^g Tianjin No 3 Medical Center   (China)

Author keywords

High risk population; Influenza; Oseltamivir; Randomized controlled trial

Indexed keywords

ANTIBIOTIC AGENT; OSELTAMIVIR; PARACETAMOL;

ADULT; AGED; ASTHMA; BRONCHIECTASIS; CHINA; CHINESE; CHRONIC BRONCHITIS; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EMPHYSEMA; FEMALE; FEVER; HEALTH CARE COST; HEART DISEASE; HIGH RISK PATIENT; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT;

ACETAMIDES; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; POPULATION; RISK; TREATMENT OUTCOME;

EID: 30844449443     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80297     Document Type: Conference Paper

References (20)

1. Lin JT, Yu XZ, Cui DJ, et al. A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population. Zhonghua Jie He He Hu Xi Za Zhi 2004;27:455-9
2. Glezen WP, Keitel WA, Taber LH, et al. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol 1991;133(3):296-304
3. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001;61(2):212-7
4. Langley JM, Faughnan ME; Canadian Task Force on Preventive Health Care. Prevention of influenza in the general population: recommendation statement from the Canadian Task Force on Preventive Health Care. Can Med Assoc J 2004;171(10):1169-70
5. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22:778-82
6. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial [Neuraminidase Inhibitor Flu Treatment Investigator Group]. Lancet 2000;355(9218):1845-50
7. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial [US Oral Neuraminidase Study Group]. J Am Med Assoc 2000;283(8):1016-24
8. Li L, Cai B, Wang M, et al. A multicenter clinical trial on oseltamivir treatment of influenza. Chin J Int Med 2001;40:838-42
9. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20(2):127-33
10. Li L, Cai B, Wang M, Zhu Y. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chin Med J 2003;116(1):44-8
11. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. B Med J 2003;326(7401):1235
12. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112(6):798-811
13. Barker WH, Borisute H, Cox C. A study of the impact of influenza on the functional status of frail older people. Arch Intern Med 1998;158(6):645-50
14. Upshur RE, Knight K, Goel V. Time-series analysis of the relation between influenza virus and hospital admissions of the elderly in Ontario, Canada, for pneumonia, chronic lung disease, and congestive heart failure. Am J Epidemiol 1999;149(1):85-92
15. Narukawa M, Minezaki K, Okubo M, Kario K. Impact of an influenza pandemic on the mortality of congestive heart failure in older Japanese: the 1998 Japanese influenza pandemic. J Am Geriatr Soc 2001;49(5):689-90
16. Peters Jr PH, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001;49(8):1025-31
17. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002;50:608-16
18. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163(14):1667-72
19. Nordstrom BL, Sung I, Suter P, et al. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005;21:761-8
20. O'Connor S, Rifkin D, Yang YH, et al. Physician control of pediatric antimicrobial use in Beijing, China, and its rural environs. Pediatr Infect Dis J 2001;20:679-84